161 results about "Cyrtanthus elatus virus A" patented technology

The invention provides novel compounds having the general formula:

wherein R¹, R², R³, R⁴, R⁵, M and X are as described herein, compositions including the compounds and methods of using the compounds.

The invention provides novel compounds having the general formula:

wherein R¹ to R⁶, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

The invention relates to an RNA interference target for treating hepatitis B virus infection with 42 different targeting hepatitis B viruses (HBV), which can be used for preparing a medicament for treating the hepatitis B virus infection. The invention provides a recombinant expression vector of siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide, which can be used for expressing targeting HBV. The invention relates to a cell which has the function of inhibiting the expression of HBV virus gene and can express and/or is induced with the siRNA and/or the miRNA and/or the ribozyme and/or the antisense oligonucleotide and/or the medication obtained according to the RNA interference target.

This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection.

The invention belongs to the field of immunodetection and discloses a method for the quantitative determination of specific cytotoxicityT lymphocyte of hepatitis B virus. The method adopts the technical proposal that the major histocompatibility compound of antigen peptide pentamer, a mouse anti-human CD3 monoclonal antibody and a mouse anti-human CD8 monoclonal antibody which are labeled by different fluoresceins are incubated with the anticoagulant peripheral blood of an HLA-A0201 or HLA-A2402 positive masculine hepatitis B virus carrier for a proper period; and after the operations of hematid schizolysis, centrifugal washing and cell fixation are completed, the CD3 gating technique is used for the quantitative determination of the specific cytotoxicityT lymphocyte of hepatitis B virus on a flow cytometry. The invention can increase the determination of the specificity, the sensitivity and the stability of the specific CTL.

The invention discloses a making method of purine derivant with maleate monohydrate, which also provides drug composition to treat hepatitis B and/or accompanying infection.

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

The invention relates to the field of polypeptide medicament, and particularly relates to an anti-hepatitis B virus X protein peptide and polypeptide coding the peptide, and application thereof. Specifically, the invention relates to a polypeptide with functional activity to inhibit hepatitis B virus X protein (HBx) at the molecular level, cellular level and animal level, and therefore can inhibit hepatitis caused by hepatitis B virus infection of, cirrhosis caused by repeated attack of hepatitis, and the liver cancer occurred on the basis of cirrhosis. The polypeptide and peptide analogs thereof including their functional fragments and functional variants, and the genes encoding these peptides, peptide analogs or their functional fragments and functional variants can be widely used for the prevention and control of hepatopathy after hepatitis B infection including hepatitis, cirrhosis and liver cancer.

The present invention provides a special high affinity anti-HBV antibody, an antigen-binding fragment and a composition thereof. The present invention provides isolated nucleic acid molecule encoding the antibody or the antigen-binding fragment. The present invention further provides a drug and/or a diagnostic composition containing the antibody, the antigen-binding fragment or the antibody composition, and uses and methods of the antibody or the antigen-binding fragment for prevention, treatment and/or diagnosis of HBV infections.